A Phase 1 interventional study of JNJ-64565111 and Placebo in Healthy, sponsored by Janssen Pharmaceutical K.K.. Terminated at 2 sites in Japan. Open to male participants aged 20 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-03.
Sponsored by Janssen Pharmaceutical K.K. (part of Johnson & Johnson) · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to assess the safety, tolerability, and pharmacokinetics (PK) of JNJ-64565111 following single and multiple subcutaneous (SC) doses in healthy Japanese male participants.
Janssen Pharmaceutical K.K. is the lead sponsor of 126 studies on the registry; none are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 7 (50%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in Cohorts 1 to 3 will receive a single Subcutaneous (SC) low, medium, and high dose of JNJ-64565111 or a JNJ-64565111 matched placebo respectively on Day 1, under fasted conditions in healthy Japanese male participants. Doses in subsequent cohorts will be escalated based on review of Principal Investigator and the Sponsor's decision after safety, tolerability review to determine safe and maximum well tolerated dose.
Drug: JNJ-64565111 · Drug: Placebo
Participants in Cohorts 4 to 5 will receive weekly multiple SC low and high dose of JNJ-64565111 or a JNJ-64565111 matched placebo respectively on Day 1, under fasted conditions in healthy Japanese male participants. If multiple high dose is judged as not tolerable, additional optional Cohort 6 will be added to Part 2 to investigate the safety, tolerability and PK after administration of multiple medium dose of JNJ-64565111 in healthy Japanese male participants. Doses in subsequent cohorts will be escalated based on review of Principal Investigator and the Sponsor's decision after safety and tolerability review to determine safe and maximum well tolerated dose.
Drug: JNJ-64565111 · Drug: Placebo
Participants in Cohort 7 will receive a single SC medium dose of JNJ-64565111 which may be started (as early as) in parallel with Cohort 3 in Part 1 on Day 1, under fasted conditions in healthy Caucasian male participants. Based on the results from Cohort 1 to 3 in Part 1, the dose of Cohort 7 may be reduced to low dose or increased to high dose.
Drug: JNJ-64565111
Participants in Cohorts 1 to 3 will receive a single SC low, medium, and high dose of JNJ-64565111 respectively on Day 1, participants in Cohorts 4 to 6 will receive weekly multiple SC low, high and medium dose of JNJ-64565111 respectively on Days 1, 8, 15, and 22, under fasted conditions. Participants in Cohort 7 will receive a single SC medium dose of JNJ-64565111 on Day 1, under fasted conditions.
Participants will receive SC injection of matching placebo on Day 1 in all cohorts of Part 1 and on Days 1, 8, 15, and 22 in Part 2 under fasted conditions.
Part 1 and Part 3: Number of Participants With Adverse Events (AEs) as a Measure of Safety and Tolerability
An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non investigational) product, whether or not related to that medicinal (investigational or non investigational) product.
Time frame: Up to Day 35
Part 1: Maximum Observed Serum Concentration (Cmax) of JNJ-64565111
Cmax is defined as the maximum observed serum concentration.
Time frame: Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose
Part 1: Actual Sampling Time to Reach Maximum Observed Serum Concentration (Tmax) of JNJ-64565111
Tmax is defined as the actual sampling time to reach maximum observed serum concentration of JNJ-64565111.
Time frame: Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose
Part 1: Area Under Serum Concentration Curve From Time 0 to Time of the Last Measurable Concentration (AUC[0-Last]) of JNJ-64565111
AUC(0-Last) is defined as the AUC from time 0 to the time of the last measurable (non-below quantification limit \[non-BQL\]) serum concentration.
Time frame: Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose
Part 1: Area Under the Serum Concentration-Time Curve From Time 0 to Infinity (AUC[0-Infinity]) of JNJ-64565111
AUC (0-infinity) is defined as the area under the serum concentration-time curve from time zero to infinite time calculated as the sum of AUC(0-last) and Clast/ lambda (z); wherein AUC(0-last) is area under the serum concentration time curve from time zero to last measurable serum concentration, Clast is the last observed measurable (non-BQL) serum concentration, and lambda (z) is the apparent terminal elimination rate constant.
Time frame: Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose
Part 1: Apparent Terminal Elimination Half-Life (t1/2) of JNJ-64565111
t1/2 is defined as the apparent terminal elimination half life, and is calculated as 0.693/lambda (z).
Time frame: Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose
Part 1: Apparent Volume of Distribution (V/F) of JNJ-64565111
V/F is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Apparent volume of distribution after subcutaneous dose (V/F) is influenced by the fraction absorbed and calculated as dose/(lambda (z)\*AUC\[0-infinity\]).
Time frame: Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose
Part 1: Total Apparent Clearance (CL/F) of JNJ-64565111
CL/F is defined as the total apparent clearance of drug after extravascular administration calculated as: dose divided by AUC\[0-infinity\].
Time frame: Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose
Part 2: Number of Participants With AEs as a Measure of Safety and Tolerability
An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non investigational) product, whether or not related to that medicinal (investigational or non investigational) product.
Time frame: Up to Day 72
Part 2: Maximum Observed Serum Concentration (Cmax) of JNJ-64565111
Cmax is defined as the maximum observed serum concentration.
Time frame: Day 1: Predose, 8, 24, 48, 72, 120 hours postdose; Day 22: Predose, 72, 96, 144, 168, 312, 480, 720, 1200 hours postdose
Part 2: Actual Sampling Time to Reach Maximum Observed Serum Concentration (Tmax) of JNJ-64565111
Tmax is defined as the actual sampling time to reach maximum observed serum concentration of JNJ-64565111.
Time frame: Day 1: Predose, 8, 24, 48, 72, 120 hours postdose; Day 22: Predose, 72, 96, 144, 168, 312, 480, 720, 1200 hours postdose
Part 2: Apparent Terminal Elimination Half-Life (t1/2) of JNJ-64565111
t1/2 is defined as the apparent terminal elimination half life, and is calculated as 0.693/lambda (z).
Time frame: Day 22: Predose, 72, 96, 144, 168, 312, 480, 720, 1200 hours postdose
Part 2: Apparent Volume of Distribution (V/F) of JNJ-64565111
V/F is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Apparent volume of distribution after subcutaneous dose (V/F) is influenced by the fraction absorbed and calculated as dose/(lambda (z)\*AUCtau).
Time frame: Day 22: Predose, 72, 96, 144, 168, 312, 480, 720, 1200 hours postdose
Part 2: Total Apparent Clearance (CL/F) of JNJ-64565111
CL/F is the total apparent clearance of drug after extravascular administration calculated as: dose divided by AUCtau.
Time frame: Day 22: Predose, 72, 96, 144, 168, 312, 480, 720, 1200 hours postdose
Part 2: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of JNJ-64565111
AUCtau is defined as the measure of the serum drug concentration from time zero to end of dosing interval.
Time frame: Day 1: Predose, 8, 24, 48, 72, 120, 168 hours postdose; Day 22: 72, 96, 144, 168 hours postdose
Part 2: Observed Serum Concentration Just Prior to the Beginning or the End of a Dosing Interval (Ctrough) of JNJ-64565111
Ctrough is defined as the observed serum concentration just prior to the beginning or the end of a dosing interval.
Time frame: Day 8: Predose ; Day 15: Predose; Day 22: Predose, 168 hours postdose
Part 2: Average Concentration Over the Dosing Interval Tau (T) at Steady State (Caverage,ss) of JNJ-64565111
Caverage,ss is defined as area under the serum concentration time curve observed during a dosing interval (tau) at steady state) will be calculated as AUCtau/Tau.
Time frame: Day 22: Predose, 72, 96, 144, 168 hours postdose
Part 2: Observed Accumulation Index (AR-AUC) of JNJ-64565111
AR-AUC is determined after multiple dose administration of JNJ-64565111 and calculated by using the equation: AUCtau, Day 22 divided by AUCtau, Day 1.
Time frame: Day 1: Predose, 8, 24, 48, 72, 120, 168 hours postdose; Day 22: Predose, 72, 96, 144, 168, 312, 480, 720, 1200 hours postdose
Part 1 and 3: Number of Participants With Anti-Drug Antibodies (ADAs) to JNJ-64565111
Number of participants with anti-drug antibodies (ADAs) to JNJ-64565111 will be reported.
Time frame: Predose, 144 and 816 hours postdose
Part 1 and Part 3: Change From Baseline in Body Weight
Change from baseline in body weight will be reported.
Time frame: Baseline to Day 35
Part 1 and Part 3: Change from Baseline in Fasting Plasma Glucose (FPG) Levels
Change from baseline in FPG levels will be reported.
Time frame: Baseline to Day 35
Part 1 and Part 3: Change From Baseline in Total Cholesterol
Change from baseline in total cholesterol will be reported.
Time frame: Baseline to Day 35
Part 1 and Part 3: Change From Baseline in Low Density Lipoprotein- Cholesterol (LDL-C)
Change from baseline in LDL-C will be reported.
Time frame: Baseline to Day 35
Part 1 and Part 3: Change From Baseline in High-Density Lipoprotein-Cholesterol (HDL-C)
Change from baseline in HDL-C will be reported.
Time frame: Baseline to Day 35
Part 1 and Part 3: Change From Baseline in Very Low Density Lipoprotein-Cholesterol (VLDL-C)
Change from baseline in VLDL-C will be reported.
Time frame: Baseline to Day 35
Part 1 and Part 3: Change From Baseline in Triglycerides
Change from baseline in Triglycerides will be reported.
Time frame: Baseline to Day 35
Part 1 and Part 3: Change From Baseline in Free Fatty Acids
Change from baseline in free fatty acids will be reported.
Time frame: Baseline to Day 35
Part 2: Number of Participants With Anti-Drug Antibodies (ADAs) to JNJ-64565111
Number of participants with ADAs to JNJ-64565111 will be reported.
Time frame: Predose on Day 1, 8, 15, 22 and then at 144, 480, 720, 1200 hours postdose
Part 2: Change From Baseline in Body Weight
Change from baseline in body weight will be reported.
Time frame: Baseline to Day 72
Part 2: Change From Baseline in Fasting Plasma Glucose (FPG) Levels
Change from baseline in FPG levels will be reported.
Time frame: Baseline to Day 72
Part 2: Change From Baseline in Total Cholesterol
Change from baseline in total cholesterol will be reported.
Time frame: Baseline to Day 72
Part 2: Change From Baseline in Low Density Lipoprotein- Cholesterol (LDL-C)
Change from baseline in LDL-C will be reported.
Time frame: Baseline to Day 72
Part 2: Change From Baseline in High-Density Lipoprotein-Choelsterol (HDL-C)
Change from baseline in HDL-C will be reported.
Time frame: Baseline to Day 72
Part 2: Change From Baseline in Very Low Density Lipoprotein-Cholesterol (VLDL-C)
Change from baseline in VLDL-C will be reported.
Time frame: Baseline to Day 72
Part 2: Change From Baseline in Triglycerides
Change from baseline in triglycerides will be reported.
Time frame: Baseline to Day 72
Part 2: Change From Baseline in Free Fatty Acids
Change from baseline in free fatty acids will be reported.
Time frame: Baseline to Day 72
Part 3: Maximum Observed Serum Concentration (Cmax) of JNJ-64565111
Cmax is defined as the maximum observed serum concentration.
Time frame: Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose
Part 3: Actual Sampling Time to Reach Maximum Observed Serum Concentration (Tmax) of JNJ-64565111
Tmax is defined as the actual sampling time to reach maximum observed serum concentration of JNJ-64565111.
Time frame: Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose
Part 3: Area Under Serum Concentration Curve From Time 0 to Time of the Last Measurable Concentration (AUC[0-Last]) of JNJ-64565111
AUC(0-Last) is defined as the AUC from time 0 to the time of the last measurable non-below quantification limit serum concentration.
Time frame: Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose
Part 3: Area Under the Serum Concentration-Time Curve From Time 0 to Infinity (AUC[0-Infinity]) of JNJ-64565111
AUC (0-infinity) is defined as the area under the serum concentration-time curve from time zero to infinite time calculated as the sum of AUC(0-last) and Clast/ lambda (z); wherein AUC(0-last) is area under the serum concentration time curve from time zero to last measurable serum concentration, Clast is the last observed measurable (non-BQL) serum concentration, and lambda (z) is the apparent terminal elimination rate constant.
Time frame: Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose
Part 3: Apparent Terminal Elimination Rate Constant (Lambda [z]) of JNJ-64565111
Lambda (z) is the apparent terminal elimination rate-constant, estimated by linear regression using the terminal log linear phase of the log transformed concentration vs time curve.
Time frame: Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose
Part 3:Apparent Terminal Elimination Half-Life (t1/2) of JNJ-64565111
t1/2 is defined the apparent terminal elimination half life, and is calculated as 0.693/lambda (z).
Time frame: Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose
Part 3: Apparent Volume of Distribution (V/F) of JNJ-64565111
V/F is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Apparent volume of distribution after subcutaneous dose (V/F) is influenced by the fraction absorbed and calculated as dose/(lambda (z)\*AUC\[0-infinity\]).
Time frame: Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose
Part 3: Total Apparent Clearance (CL/F) of JNJ-64565111
CL/F is defined as the total apparent clearance of drug after extravascular administration calculated as: dose divided by AUC\[0-infinity\].
Time frame: Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose
Ran from Aug 2018 to primary completion in Jun 2019, 10 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Efinopegdutide